

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

### SECTION 1. IDENTIFICATION

Product name : Pertuzumab Biosimilar Formulation  
Other means of identification : Prescription Medicine

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey 07302

Telephone : 551-430-6000  
Emergency telephone : For 24/7 emergency response, call CHEMTREC at +1-800-424-9300 (Global, 24/7, English) or +1-703-741-5970 (United States)

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : To be dispensed by or on the prescription of physician.

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

##### Hazards for the product as supplied

Specific target organ toxicity : Category 2 (Gastrointestinal tract, Kidney)  
- repeated exposure

##### Other hazards

None known.

##### GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H373 May cause damage to organs (Gastrointestinal tract, Kidney) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**  
P260 Do not breathe mist or vapors.  
**Response:**

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version 1.0      Revision Date: 11/24/2025      SDS Number: 310000001697      Date of last issue: -  
Date of first issue: 11/24/2025

P314 Get medical advice/ attention if you feel unwell.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Pertuzumab	380610-27-5*	3	-

\* Indicates that the identifier is a CAS No.

## SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Reference Section 11: Experience with human exposure.  
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

## SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO2)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Sulfur oxides  
Nitrogen oxides (NOx)



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

Water

- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use a water spray to cool fully closed containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Clean thoroughly.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version 1.0      Revision Date: 11/24/2025      SDS Number: 310000001697      Date of last issue: -  
Date of first issue: 11/24/2025

- Conditions for safe storage : Take care to prevent spills, waste and minimize release to the environment.  
: See current prescribing information.  
Store in original container.  
Refrigeration required (2 - 8°C).  
Do not freeze.  
Do not shake.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Pertuzumab	380610-27-5	TWA	1300 µg/m <sup>3</sup> (OEB 1)	Internal

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

- Respiratory protection : No personal respiratory protective equipment normally required.  
General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection  
Material : Chemical-resistant gloves
- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

Skin and body protection : Work uniform or laboratory coat.  
Hygiene measures : The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution  
Color : Colorless to pale yellow  
Odor : odorless  
pH : 6  
Melting point/freezing point : Not applicable  
Boiling point/boiling range : not determined  
Flash point : Not applicable  
Flammability (liquids) : Will not burn  
Upper explosion limit / Upper flammability limit : Not applicable  
Lower explosion limit / Lower flammability limit : Not applicable  
Vapor pressure : not determined  
Relative vapor density : not determined  
Density : similar to water not determined  
Solubility(ies)  
Water solubility : soluble  
Partition coefficient: n-octanol/water : Not applicable  
Autoignition temperature : does not ignite  
Not applicable  
Viscosity

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

Viscosity, dynamic : not determined

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Acute toxicity

Not classified due to lack of data.

#### Components:

##### Pertuzumab:

Acute oral toxicity	: Remarks: No data available
Acute inhalation toxicity	: Remarks: No data available
Acute dermal toxicity	: Remarks: No data available
Acute toxicity (other routes of administration)	: Remarks: No data available

#### Skin corrosion/irritation

Not classified due to lack of data.

#### Components:

##### Pertuzumab:

Remarks : No data available

#### Serious eye damage/eye irritation

Not classified due to lack of data.

#### Components:

##### Pertuzumab:

Remarks : No data available

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

### Respiratory or skin sensitization

#### Skin sensitization

Not classified due to lack of data.

#### Respiratory sensitization

Not classified due to lack of data.

#### Components:

##### Pertuzumab:

Test Type	:	Skin sensitization
Assessment	:	Not classified
Remarks	:	No data available

Test Type	:	Respiratory sensitization
Assessment	:	Not classified
Remarks	:	No data available

As a class, protein-based therapeutics have been shown to have the potential to cause respiratory sensitization

### Germ cell mutagenicity

Not classified due to lack of data.

#### Components:

##### Pertuzumab:

Genotoxicity in vitro	:	Remarks: Not classified
-----------------------	---	-------------------------

Genotoxicity in vivo	:	Remarks: Not classified
----------------------	---	-------------------------

Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen., Based on the size and properties of the material (monoclonal antibody), there is not potential to be a direct-acting mutagen.
-------------------------------------	---	---

### Carcinogenicity

Not classified due to lack of data.

#### Components:

##### Pertuzumab:

Remarks	:	Not classified
---------	---	----------------

Carcinogenicity - Assessment	:	Not classified, Based on the size and properties of the material (monoclonal antibody), there is not potential to be a direct-acting carcinogen.
------------------------------	---	--

IARC	No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
------	--

OSHA	No component of this product present at levels greater than or equal to 0.1% is
------	---



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version 1.0	Revision Date: 11/24/2025	SDS Number: 310000001697	Date of last issue: - Date of first issue: 11/24/2025
----------------	------------------------------	-----------------------------	--

on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### **Pertuzumab:**

Effects on fertility	: Remarks: No data available
Effects on fetal development	: Test Type: One-generation reproduction toxicity study Species: Monkey Application Route: Intravenous Frequency of Treatment: 1 daily General Toxicity Maternal: NOAEL: 100 mg/kg body weight Embryo-fetal toxicity.: LOAEL: 10 mg/kg body weight Symptoms: Embryolethal effects., Specific developmental abnormalities. Target Organs: Kidney Result: Embryolethal effects., Specific developmental abnormalities.

### STOT-single exposure

Not classified due to lack of data.

### STOT-repeated exposure

May cause damage to organs (Gastrointestinal tract, Kidney) through prolonged or repeated exposure.

#### Components:

##### **Pertuzumab:**

Target Organs	: Gastrointestinal tract, Kidney
Assessment	: May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### **Pertuzumab:**

Species	: Monkey
LOAEL	: 15 mg/kg
Application Route	: Intravenous
Exposure time	: 26 weeks
Number of exposures	: weekly
Target Organs	: Gastrointestinal tract, Kidney
Symptoms	: diarrhea, Dehydration



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

---

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Pertuzumab:

Not applicable

### Experience with human exposure

#### Product:

General Information : Symptoms: diarrhea, nausea, Vomiting, joint pain, muscle weakness, decrease in appetite, breathing difficulties, fatigue, rash, Itching

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### Pertuzumab:

#### Ecotoxicology Assessment

Acute aquatic toxicity : No data available  
Remarks: Not classified

Chronic aquatic toxicity : No data available  
Remarks: Not classified

### Persistence and degradability

#### Components:

#### Pertuzumab:

Biodegradability : Remarks: Expected to be biodegradable

### Bioaccumulative potential

No data available

### Mobility in soil

No data available

### Other adverse effects

#### Product:

Endocrine disrupting potential : Does not have endocrine disrupting properties.

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

### Substances

Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

Not regulated as a dangerous good

### Special precautions for user

Not applicable

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Specific target organ toxicity (single or repeated exposure)

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

### Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

### US State Regulations

#### Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

#### Pennsylvania Right To Know

water	7732-18-5
D-glucitol	50-70-4
Pertuzumab	380610-27-5

#### Maine Chemicals of High Concern

Product does not contain any listed chemicals

#### Vermont Chemicals of High Concern

Product does not contain any listed chemicals

#### Washington Chemicals of High Concern

Product does not contain any listed chemicals

### The ingredients of this product are reported in the following inventories:

AICS	: All ingredients listed or exempt.
CA. DSL	: All ingredients listed or exempt.
IECSC	: All ingredients listed or exempt.
EINECS	: All ingredients listed or exempt.
TSCA	: All ingredients listed or exempt.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation


Version 1.0	Revision Date: 11/24/2025	SDS Number: 310000001697	Date of last issue: - Date of first issue: 11/24/2025
----------------	------------------------------	-----------------------------	--

ENCS : All ingredients listed or exempt.

### SECTION 16. OTHER INFORMATION

#### Further information

##### NFPA 704:



##### HMIS® IV:

HEALTH	*	2
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pertuzumab Biosimilar Formulation

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	11/24/2025	310000001697	Date of first issue: 11/24/2025

---

Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 11/24/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN